

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

<b>In the Matter of the Accusation</b>	)	
<b>Against:</b>	)	
	)	
	)	
<b>YASHWANT S. CHAUDHRI, M.D.</b>	)	<b>Case No. 800-2016-021067</b>
	)	
<b>Physician's and Surgeon's</b>	)	
<b>Certificate No. A67679</b>	)	
	)	
<b>Respondent</b>	)	
_____	)	


**DECISION**

**The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.**

**This Decision shall become effective at 5:00 p.m. on September 27, 2019.**

**IT IS SO ORDERED August 28, 2019.**

**MEDICAL BOARD OF CALIFORNIA**



\_\_\_\_\_  
**Ronald H. Lewis, M.D., Chair**  
**Panel A**

1 XAVIER BECERRA  
Attorney General of California  
2 ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General  
3 ROSEMARY F. LUZON  
Deputy Attorney General  
4 State Bar No. 221544  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9074  
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9  
10 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
11 **DEPARTMENT OF CONSUMER AFFAIRS**  
**STATE OF CALIFORNIA**  
12

13 In the Matter of the Accusation Against:

Case No. 800-2016-021067

14 **Yashwant S. Chaudhri, M.D.**  
15 **4537 College Avenue**  
**San Diego, CA 92115**

OAH No. 2019030763

16 **Physician's and Surgeon's Certificate**  
17 **No. A 67679,**

**STIPULATED SETTLEMENT AND**  
**DISCIPLINARY ORDER**

18 Respondent.

19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
20 entitled proceedings that the following matters are true:

21 **PARTIES**

22 1. Kimberly Kirchmeyer (Complainant) is the Executive Director of the Medical Board  
23 of California (Board). She brought this action solely in her official capacity and is represented in  
24 this matter by Xavier Becerra, Attorney General of the State of California, by Rosemary F.  
25 Luzon, Deputy Attorney General.

26 2. Respondent Yashwant S. Chaudhri, M.D. (Respondent) is represented in this  
27 proceeding by attorney Kevin C. Murphy, Esq., whose address is: 5575 Lake Park Way, Suite  
28 218, La Mesa, CA 91942.



1 **CULPABILITY**

2 8. Respondent does not contest that, at an administrative hearing, Complainant could  
3 establish a *prima facie* case with respect to the charges and allegations contained in Accusation  
4 No. 800-2016-021067, a copy of which is attached hereto as Exhibit A, and that he has thereby  
5 subjected Physician's and Surgeon's Certificate No. A 67679 to disciplinary action.

6 9. Respondent agrees that if an accusation is ever filed against him before the Medical  
7 Board of California, all of the charges and allegations contained in Accusation No. 800-2016-  
8 021067 shall be deemed true, correct and fully admitted by Respondent for purposes of that  
9 proceeding or any other licensing proceeding involving Respondent in the State of California.

10 10. Respondent agrees that his Physician's and Surgeon's Certificate No. A 67679 is  
11 subject to discipline and he agrees to be bound by the Board's imposition of discipline as set forth  
12 in the Disciplinary Order below.

13 **CONTINGENCY**

14 11. This Stipulated Settlement and Disciplinary Order shall be subject to approval of the  
15 Board. The parties agree that this Stipulated Settlement and Disciplinary Order shall be  
16 submitted to the Board for its consideration in the above-entitled matter and, further, that the  
17 Board shall have a reasonable period of time in which to consider and act on this Stipulated  
18 Settlement and Disciplinary Order after receiving it. By signing this stipulation, Respondent fully  
19 understands and agrees that he may not withdraw his agreement or seek to rescind this stipulation  
20 prior to the time the Board considers and acts upon it.

21 12. The parties agree that this Stipulated Settlement and Disciplinary Order shall be null  
22 and void and not binding upon the parties unless approved and adopted by the Board, except for  
23 this paragraph, which shall remain in full force and effect. Respondent fully understands and  
24 agrees that in deciding whether or not to approve and adopt this Stipulated Settlement and  
25 Disciplinary Order, the Board may receive oral and written communications from its staff and/or  
26 the Attorney General's Office. Communications pursuant to this paragraph shall not disqualify  
27 the Board, any member thereof, and/or any other person from future participation in this or any  
28 other matter affecting or involving Respondent. In the event that the Board does not, in its

1 discretion, approve and adopt this Stipulated Settlement and Disciplinary Order, with the  
2 exception of this paragraph, it shall not become effective, shall be of no evidentiary value  
3 whatsoever, and shall not be relied upon or introduced in any disciplinary action by either party  
4 hereto. Respondent further agrees that should this Stipulated Settlement and Disciplinary Order  
5 be rejected for any reason by the Board, Respondent will assert no claim that the Board, or any  
6 member thereof, was prejudiced by its/his/her review, discussion and/or consideration of this  
7 Stipulated Settlement and Disciplinary Order or of any matter or matters related hereto.

8 **ADDITIONAL PROVISIONS**

9 13. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to  
10 be an integrated writing representing the complete, final and exclusive embodiment of the  
11 agreements of the parties in the above-entitled matter.

12 14. The parties understand and agree that Portable Document Format (PDF) and facsimile  
13 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile  
14 signatures thereto, shall have the same force and effect as the originals.

15 15. In consideration of the foregoing admissions and stipulations, the parties agree that  
16 the Board may, without further notice or opportunity to be heard by Respondent, issue and enter  
17 the following Disciplinary Order:

18 **DISCIPLINARY ORDER**

19 1. **PUBLIC REPRIMAND.**

20 IT IS HEREBY ORDERED that Respondent Yashwant S. Chaudhri, M.D., Physician's and  
21 Surgeon's Certificate No. A 67679, shall be and is hereby Publicly Reprimanded pursuant to  
22 California Business and Professions Code section 2227, subdivision (a), subsection (4). This  
23 Public Reprimand, which is issued in connection Respondent's care and treatment of Patient A, as  
24 set forth in Accusation No. 800-2016-021067, is as follows:

25 ///

26 ///

27 ///

28 ///

1 Respondent did not properly document multiple aspects of Patient A's care, including  
2 informed consent for treatment with psychiatric medications, the rationale for  
3 changes in the medication regimen, maintenance of comprehensive medical records,  
4 and timely dictation of admission evaluations; Respondent did not properly terminate  
5 his care of Patient A; and Respondent did not timely review, consider, and/or  
6 clinically respond to pertinent information regarding Patient A's care and changes in  
7 condition, as more fully described in Accusation No. 800-2016-021067, a true and  
8 correct copy of which is attached hereto as Exhibit A and incorporated by reference  
9 as if fully set forth herein.

10 2. PRESCRIBING PRACTICES COURSE.

11 Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
12 course in prescribing practices approved in advance by the Board or its designee. Respondent  
13 shall provide the approved course provider with any information and documents that the approved  
14 course provider may deem pertinent. Respondent shall participate in and successfully complete  
15 the classroom component of the course not later than six (6) months after Respondent's initial  
16 enrollment. Respondent shall successfully complete any other component of the course within  
17 one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense  
18 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of  
19 licensure.

20 A prescribing practices course taken after the acts that gave rise to the charges in the  
21 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
22 or its designee, be accepted towards the fulfillment of this condition if the course would have  
23 been approved by the Board or its designee had the course been taken after the effective date of  
24 this Decision.

25 Respondent shall submit a certification of successful completion to the Board or its  
26 designee not later than 15 calendar days after successfully completing the course, or not later than  
27 15 calendar days after the effective date of the Decision, whichever is later.

28 ///

1           3.    MEDICAL RECORD KEEPING COURSE.

2           Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
3 course in medical record keeping approved in advance by the Board or its designee. Respondent  
4 shall provide the approved course provider with any information and documents that the approved  
5 course provider may deem pertinent. Respondent shall participate in and successfully complete  
6 the classroom component of the course not later than six (6) months after Respondent's initial  
7 enrollment. Respondent shall successfully complete any other component of the course within  
8 one (1) year of enrollment. The medical record keeping course shall be at Respondent's expense  
9 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of  
10 licensure.

11           A medical record keeping course taken after the acts that gave rise to the charges in the  
12 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
13 or its designee, be accepted towards the fulfillment of this condition if the course would have  
14 been approved by the Board or its designee had the course been taken after the effective date of  
15 this Decision.

16           Respondent shall submit a certification of successful completion to the Board or its  
17 designee not later than 15 calendar days after successfully completing the course, or not later than  
18 15 calendar days after the effective date of the Decision, whichever is later.

19           4.    CLINICAL COMPETENCE ASSESSMENT PROGRAM.

20           Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
21 clinical competence assessment program approved in advance by the Board or its designee.  
22 Respondent shall successfully complete the program not later than six (6) months after  
23 Respondent's initial enrollment unless the Board or its designee agrees in writing to an extension  
24 of that time.

25           The program shall consist of a comprehensive assessment of Respondent's physical and  
26 mental health and the six general domains of clinical competence as defined by the Accreditation  
27 Council on Graduate Medical Education and American Board of Medical Specialties pertaining to  
28 Respondent's current or intended area of practice. The program shall take into account data

1 obtained from the pre-assessment, self-report forms and interview, and the Decision(s),  
2 Accusation(s), and any other information that the Board or its designee deems relevant. The  
3 program shall require Respondent's on-site participation for a minimum of three (3) and no more  
4 than five (5) days as determined by the program for the assessment and clinical education  
5 evaluation. Respondent shall pay all expenses associated with the clinical competence  
6 assessment program.

7 At the end of the evaluation, the program will submit a report to the Board or its designee  
8 which unequivocally states whether the Respondent has demonstrated the ability to practice  
9 safely and independently. Based on Respondent's performance on the clinical competence  
10 assessment, the program will advise the Board or its designee of its recommendation(s) for the  
11 scope and length of any additional educational or clinical training, evaluation or treatment for any  
12 medical condition or psychological condition, or anything else affecting Respondent's practice of  
13 medicine. Respondent shall comply with the program's recommendations.

14 Determination as to whether Respondent successfully completed the clinical competence  
15 assessment program is solely within the program's jurisdiction.

16 If Respondent fails to enroll, participate in, or successfully complete the clinical  
17 competence assessment program within the designated time period, Respondent shall receive a  
18 notification from the Board or its designee to cease the practice of medicine within three (3)  
19 calendar days after being so notified. The Respondent shall not resume the practice of medicine  
20 until enrollment or participation in the outstanding portions of the clinical competence assessment  
21 program have been completed. If the Respondent did not successfully complete the clinical  
22 competence assessment program, the Respondent shall not resume the practice of medicine until a  
23 final decision has been rendered on the accusation and/or a petition to revoke probation. The  
24 cessation of practice shall not apply to the reduction of the probationary time period.


25 5. FAILURE TO COMPLY.

26 Any failure by Respondent to comply with the terms and conditions of the Disciplinary  
27 Order set forth above shall constitute unprofessional conduct and grounds for further disciplinary  
28 action.




1 **ACCEPTANCE**

2 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
3 discussed it with my attorney, Kevin C. Murphy, Esq. I understand the stipulation and the effect  
4 it will have on my Physician's and Surgeon's Certificate No. A 67679. I enter into this Stipulated  
5 Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be  
6 bound by the Decision and Order of the Medical Board of California.

7  
8 DATED: 08-02-2019   
9 YASHWANT S. CHAUDHRI, M.D.  
10 *Respondent*

11 I have read and fully discussed with Respondent Yashwant S. Chaudhri, M.D., the terms  
12 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary  
13 Order. I approve its form and content.

14  
15 DATED: 8/3/19   
16 KEVIN C. MURPHY, ESQ.  
17 *Attorney for Respondent*

18 **ENDORSEMENT**

19 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully  
20 submitted for consideration by the Medical Board of California.

21  
22 DATED: \_\_\_\_\_ Respectfully submitted,  
23 XAVIER BECERRA  
24 Attorney General of California  
25 ALEXANDRA M. ALVAREZ  
26 Supervising Deputy Attorney General

27 ROSEMARY F. LUZON  
28 Deputy Attorney General  
*Attorneys for Complainant*

SD2019700400771926302.docx

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**ACCEPTANCE**

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Kevin C. Murphy, Esq. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate No. A 67679. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: \_\_\_\_\_  
YASHWANT S. CHAUDHRI, M.D.  
*Respondent*


I have read and fully discussed with Respondent Yashwant S. Chaudhri, M.D., the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: \_\_\_\_\_  
KEVIN C. MURPHY, ESQ.  
*Attorney for Respondent*

**ENDORSEMENT**

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: 8/5/19

Respectfully submitted,  
XAVIER BECERRA  
Attorney General of California  
ALEXANDRA M. ALVAREZ  
Supervising Deputy Attorney General  
  
ROSEMARY F. LUZON  
Deputy Attorney General  
*Attorneys for Complainant*

**Exhibit A**

**Accusation No. 800-2016-021067**



**JURISDICTION**

1  
2       3.    This Accusation is brought before the Board, under the authority of the following  
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise  
4 indicated.

5       4.    Section 2220 of the Code states:

6            “Except as otherwise provided by law, the board may take action against all  
7 persons guilty of violating this chapter. . .”

8       5.    Section 2227 of the Code states:

9            “(a) A licensee whose matter has been heard by an administrative law judge of  
10 the Medical Quality Hearing Panel as designated in Section 11371 of the Government  
11 Code, or whose default has been entered, and who is found guilty, or who has entered  
12 into a stipulation for disciplinary action with the board, may, in accordance with the  
13 provisions of this chapter:

14            “(1) Have his or her license revoked upon order of the board.

15            “(2) Have his or her right to practice suspended for a period not to exceed one  
16 year upon order of the board.

17            “(3) Be placed on probation and be required to pay the costs of probation  
18 monitoring upon order of the board.

19            “(4) Be publicly reprimanded by the board. The public reprimand may include  
20 a requirement that the licensee complete relevant educational courses approved by the  
21 board.

22            “(5) Have any other action taken in relation to discipline as part of an order of  
23 probation, as the board or an administrative law judge may deem proper.

24            “. . .”

25       6.    Section 2234 of the Code states:

26            “The board shall take action against any licensee who is charged with  
27 unprofessional conduct. In addition to other provisions of this article, unprofessional  
28 conduct includes, but is not limited to, the following:



1 **FIRST CAUSE FOR DISCIPLINE**

2 **(Gross Negligence)**

3 9. Respondent has subjected his Physician's and Surgeon's Certificate No. A 67679 to  
4 disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (b), of  
5 the Code, in that he committed gross negligence in his care and treatment of Patient A, as more  
6 particularly alleged hereinafter:<sup>1</sup>

7 10. On or about June 22, 2013, Patient A went to Respondent's office in Santee,  
8 California to commence outpatient psychiatric treatment. Patient A was seen by Respondent's  
9 Nurse Practitioner, D.G.

10 11. According to the notes prepared by Nurse Practitioner D.G. for the June 22, 2013,  
11 visit, Patient A had a history of depression and the purpose for the visit was medication  
12 management. The notes also indicated that Patient A's primary care provider had prescribed a  
13 six-month supply of psychiatric medications to Patient A, but he ran out of the medications 10  
14 days earlier. Patient A's psychiatric medications included Risperdal (risperidone) 2 mg twice  
15 daily,<sup>2</sup> Depakote (depakote divalproex sodium) 1500 mg once daily,<sup>3</sup> and Paxil (paroxetine) 80  
16 mg once daily.<sup>4</sup> Patient A was noted as having a history of a psychiatric hospitalization three  
17 years earlier, neurosyphilis, encephalitis, and use of cannabis since age 17, with the last use being  
18 on or about June 21, 2013. Patient A was also noted as having a medical marijuana card. A  
19 mental status examination was performed and the following psychiatric diagnoses were noted:  
20 Axis I (Bipolar Disorder); Axis II (none); Axis III (history of encephalitis and neurosyphilis); and  
21 Axis IV (psychosocial environmental stressors secondary to chronic mental illness). No Axis V  
22 assessment was provided.

23 ///

24  
25 <sup>1</sup> References to "Patient A" herein are used to protect patient privacy.

26 <sup>2</sup> Risperdal is an atypical antipsychotic medication that is used to treat certain  
27 mental/mood disorders, such as schizophrenia and bipolar disorder.

28 <sup>3</sup> Depakote is an anticonvulsant medication that is used to treat the manic symptoms of  
bipolar disorder.

<sup>4</sup> Paxil is a medication that is used to treat depression, panic attacks, and anxiety disorders.

1           12. The treatment plan for the June 22, 2013, visit, was to continue with Patient A's  
2 current medication regimen as follows: Risperdal 2 mg twice daily, Depakote 1500 mg once  
3 daily, and Paxil 40 mg once daily. The notes did not include any explanation for reducing the  
4 daily dosage of Paxil from 80 mg to 40 mg, nor did they document any discussion of this change  
5 with Patient A. On or about June 23, 2013, Respondent signed Nurse Practitioner D.G.'s notes  
6 for this visit and, next to his signature, Respondent handwrote the following statement:  
7 "Reviewed assessment and agreed with the treatment plan."

8           13. On or about July 8, 2013, and August 5, 2013, respectively, Patient A had a follow-up  
9 visit with Nurse Practitioner D.G. at Respondent's office. According to the notes prepared by  
10 Nurse Practitioner D.G. for these visits, Patient A reported compliance with the medication  
11 regimen with no side effects and improved sleeping and eating. A mental status examination was  
12 performed and the same prior psychiatric diagnoses were noted. The treatment plan was to  
13 continue with Patient A's current medication regimen, including Risperdal, Depakote, and Paxil,  
14 along with psychoeducation on psychotropic medicines. Patient A was to return in four weeks.  
15 On or about July 8, 2013, and August 5, 2013, respectively, both Nurse Practitioner D.G. and  
16 Respondent signed the notes for these visits.

17           14. On or about September 4, 2013, Respondent saw Patient A at Respondent's office.  
18 According to Respondent's notes, Patient A reported compliance with the medication regimen  
19 with no side effects and improved sleeping and eating. In addition, Patient A expressed his desire  
20 to continue with the same medications. A mental status examination was performed and the same  
21 prior psychiatric diagnoses were noted, along with an Axis V Global Assessment of Functioning  
22 (GAF) score of 54. The treatment plan was to continue with Patient A's current medication  
23 regimen, however, only Risperdal and Paxil were listed. Depakote was not included on the list of  
24 medications. Respondent did not note the reasons for stopping Depakote, nor did he document  
25 any discussion of this change with Patient A.

26           15. On or about December 19, 2013, Patient A was seen at Respondent's office.  
27 According to the notes for this visit, Patient A reported compliance with the medication regimen  
28 with no side effects and improved sleeping and eating. However, Patient A reported that while he



1 continued to take Risperdal and Paxil, he discontinued Depakote on his own. The notes did not  
2 document when Patient A stopped taking Depakote, the reasons for doing so, the risks of stopping  
3 Depakote, or the need to change the treatment plan. The treatment plan was to continue with  
4 Patient A's current medication regimen with respect to Risperdal and Paxil only. Due to Patient  
5 A's extended trip to New Orleans, Patient A was to return in six months. The notes for this visit  
6 were signed by Respondent on or about December 19, 2013.

7 16. On or about June 20, 2014, Patient A was again seen at Respondent's office.  
8 According to the notes for this visit, Patient A reported compliance with the medication regimen  
9 and improved sleeping and eating. The treatment plan was to continue with Patient A's current  
10 medication regimen, which, in addition to Risperdal and Paxil, now included Depakote 1000 mg  
11 daily. The notes did not document any discussion with Patient A regarding restarting Depakote,  
12 nor did they document the clinical rationale for stopping and restarting the medication and  
13 changing the dosage. Patient A was to return in two weeks. The notes for this visit were signed  
14 by Respondent on or about June 20, 2014.

15 17. On or about July 9, 2014, Patient A had a follow-up visit at Respondent's office and  
16 was seen by Respondent's Nurse Practitioner, B.J. According to the notes prepared by Nurse  
17 Practitioner B.J. for this visit, Patient A's current medication regimen included Risperdal, Paxil,  
18 and Depakote. The current medication regimen was discussed and the treatment plan was to  
19 decrease the Risperdal dosage to 1 mg twice daily and continue Paxil and Depakote. In addition,  
20 a laboratory test for Depakote levels was ordered for July 21, 2014. Patient A was to return on  
21 July 23, 2014. The notes for this visit were signed by Nurse Practitioner B.J. and Respondent on  
22 or about July 9, 2014.

23 18. On or about August 26, 2014, a request for refill of Patient A's Paxil medication was  
24 faxed to Respondent's office. The request was not approved and included the following notation:  
25 "Needs to see Doctor." The medical records, however, did not include any attempts by  
26 Respondent's office to contact Patient A regarding the Paxil refills, to set up an appointment with  
27 Patient A so that the medication could be refilled, or to otherwise advise Patient A that a follow-  
28 up visit was necessary to continue the medication treatment.

1           19. On or about September 15, 2014, Patient A had a follow-up visit with Nurse  
2 Practitioner D.G. at Respondent's office. According to the notes prepared by Nurse Practitioner  
3 D.G. for this visit, Patient A reported that he discontinued Depakote on his own and had to stop  
4 taking Paxil for the past two weeks because he ran out of refills and the pharmacy's refill request  
5 was declined. The treatment plan was to continue Paxil, but increase Risperdal to 2 mg twice  
6 daily and add Neurontin (gabapentin)<sup>5</sup> and Cogentin (benztropine)<sup>6</sup> to the medication regimen.  
7 The notes did not document any discussion with Patient A regarding increasing the Risperdal  
8 dosage or adding Neurontin and Cogentin, nor did they document the clinical rationale for these  
9 medication changes. In addition, the notes did not document when Patient A stopped taking  
10 Depakote, the reasons for doing so, the risks of stopping Depakote, or the need to change the  
11 treatment plan. The notes for this visit were signed by Respondent on or about September 15,  
12 2014. Respondent also added the following notation: "Patient referred to IOP, API."

13           20. On or about September 25, 2014, Patient A was admitted to the Alvarado Parkway  
14 Institute Intensive Outpatient Program (IOP). Upon admission, Patient A reported a history of  
15 substance abuse with marijuana, including daily use since age 17. Patient A also reported that the  
16 marijuana was medically prescribed. On or about the same day, Respondent issued a telephone  
17 order for Risperdal 1 mg twice daily and Depakote 1000 mg once daily, in addition to antibiotic  
18 treatment. The telephone order was signed by Respondent on or about September 29, 2014. The  
19 notes for this visit made no reference to Paxil, Neurontin, and Cogentin, which were previously  
20 prescribed to Patient A on or about September 15, 2014, and they did not reflect any discussions  
21 with Patient A regarding these medication changes.

22           21. On or about September 26, 2014, Patient A underwent a history and physical  
23 examination performed by an IOP physician, Dr. F.J. Patient A was noted to be "off his  
24 psychotropic medications[,]" with admitted alcohol drinking and daily use of marijuana.

25 ///

26 \_\_\_\_\_  
27 <sup>5</sup> Neurontin is an anticonvulsant medication that is used with other medications to prevent  
and control seizures and relieve postherpetic neuralgia.

28 <sup>6</sup> Cogentin is a medication that is used to treat symptoms of Parkinson's disease or  
involuntary movements due to the side effects of certain psychiatric drugs.

1           22. On or about September 29, 2014, Respondent made a handwritten note stating that a  
2 psychiatric evaluation was done. Respondent noted the following psychiatric diagnoses: Axis I  
3 (bipolar I disorder, mixed, severe with no psychosis; cannabis dependence); Axis II (deferred);  
4 Axis III (hyperlipidemia, neurosyphilis, GERD); Axis IV (blank); and Axis 5 (highest GAF in  
5 past year: 52, current GAF: 30). Respondent did not include any information regarding  
6 symptoms, impairments, medications, or treatment objectives for Patient A.

7           23. On or about September 30, 2014, an IOP Interdisciplinary Master Treatment Plan was  
8 prepared by IOP physician, Dr. C.B. The Plan identified "Symptom Management" as the first  
9 problem and a history of medication and treatment non-compliance by Patient A, including  
10 attempts to adjust medications without psychiatrist consultation. The diagnoses were noted as  
11 follows: Axis I (bipolar I disorder, most recent episode depressed); Axis II (deferred); Axis III  
12 (neurosyphilis, hyperlipidemia, hypertriglyceridemia, GERD); Axis IV (severe, primary support  
13 and social environment); Axis V (GAF: current 30).

14           24. On or about October 16, 2014, Patient A was seen by IOP physician, Dr. C.B. The  
15 treatment plan was to continue Depakote and Risperdal as prescribed and refer Patient A back to  
16 Respondent for any further interventions.

17           25. On or about October 28, 2014, Respondent dictated his Psychiatric Admission  
18 Evaluation for Patient A. The note was not signed until on or about November 17, 2014.  
19 Respondent summarized Patient A's clinical history and reason for admission. The psychiatric  
20 diagnoses were noted as follows: Axis I (bipolar I disorder, mixed, severe without psychotic  
21 features; cannabis abuse); Axis II (deferred); Axis III (neurosyphilis, hyperlipidemia,  
22 gastroesophageal reflux disease); Axis IV (psychosocial and environmental stress secondary to  
23 chronic mental illness); Axis 5 (GAF: on admission 28).

24           26. On or about October 29, 2014, the IOP Interdisciplinary Treatment Plan was updated  
25 by IOP physician, Dr. B.S. The update noted that Patient A continued to use marijuana on a daily  
26 basis and was sent home one day as a result of coming to the program under the influence of  
27 marijuana.

28       ///

1           27. On or about November 17, 2014, Patient A was seen by Respondent. Patient A  
2 reported medication compliance with no side effects, except for Depakote. The note stated that  
3 Depakote would be discontinued. On or about the same day, Respondent ordered that Patient A's  
4 Depakote be discontinued, however, he also issued a telephone order for three-month refills of  
5 Risperdal 1 mg twice daily and Depakote 1000 mg once daily. The telephone order was signed  
6 by Respondent on or about November 17, 2014. The note for this visit did not address the  
7 October 29, 2014, updated treatment plan and its assessments regarding Patient A's daily  
8 marijuana use, including his attendance at the program while under the influence of marijuana.

9           28. Between on or about September 25, 2014, and November 19, 2014, Patient A was  
10 prescribed Risperdal 1 mg twice daily. Between on or about September 25, 2014, and November  
11 17, 2014, Patient A was prescribed Depakote 1000 mg once daily. Beginning on or about  
12 November 19, 2014, Patient A was prescribed Risperdal 2 mg twice daily, along with gabapentin,  
13 paroxetine, and benztropine. Respondent did not document any discussion with Patient A  
14 regarding increasing the Risperdal dosage or starting gabapentin, paroxetine, and benztropine, nor  
15 did Respondent document the clinical rationale for these medication changes.

16           29. On or about November 25, 2014, the IOP Interdisciplinary Treatment Plan was  
17 updated by Respondent. The update noted that Patient A was not compliant with his Depakote  
18 medication, but was compliant with all other medications. Respondent adjusted Patient A's  
19 medications by discontinuing Depakote. Patient A reported that he continued to use marijuana,  
20 but was cutting back. The update was signed by Respondent on or about January 9, 2015.

21           30. On or about December 8, 2014, Patient A reported in group therapy that he had  
22 stopped taking his medication for depression two weeks earlier and did not inform IOP staff.

23           31. On or about December 10, 2014, a laboratory test for blood Depakote levels was  
24 ordered. According to a note dated on or about December 9, 2014, however, Patient A reported  
25 that he was not taking Depakote.

26           32. On or about December 15, 2014, Patient A was seen by Respondent. Respondent  
27 noted that Patient A was compliant with his medications and wished to continue with his  
28 medication regimen, but requested an increase of his Risperdal dosage. Respondent changed

1 Patient A's medications by increasing his Risperdal dosage to 2 mg twice daily. On or about the  
2 same day, Respondent made an order reflecting this change. On or about the same day,  
3 Respondent also issued a telephone order for three-month refills of benztropine, gabapentin, and  
4 paroxetine. The telephone order was signed by Respondent on or about January 9, 2015.

5 33. On or about December 23, 2014, the IOP Interdisciplinary Treatment Plan was  
6 updated by Respondent. According to the update, the following medications were added:  
7 resveratrol 500 mg, vitamin B12, huperzine A, milk thistle, chromium picolinate, raw probiotics,  
8 and aspirin. The update also noted Patient A's continued use of marijuana on a daily basis. The  
9 update was signed by Respondent on or about January 9, 2015.

10 34. On or about January 9, 2015, Patient A was seen by Respondent. Respondent noted  
11 that Patient A was compliant with his medications with no side effects, sleeping and eating better,  
12 and wished to continue with his medication regimen. He also noted that Patient A complained of  
13 memory problems.

14 35. On or about January 12, 2015, Respondent also issued a telephone order to refer  
15 Patient A to a neurologist for evaluation of memory and cognitive decline and appropriate  
16 treatment. Respondent signed the telephone order on or about March 2, 2015.

17 36. On or about January 20, 2015, the IOP Interdisciplinary Treatment Plan was updated  
18 by Respondent. The update noted no medication adjustments and continuing complaints of  
19 memory problems by Patient A. The update also referenced Respondent's referral of Patient A to  
20 a neurologist. The update was signed by Respondent on or about March 2, 2015.

21 37. On or about January 27, 2015, Respondent issued a telephone order for three-month  
22 refills of Risperdal 2 mg twice daily as well as benztropine, gabapentin, and paroxetine. The  
23 telephone order was signed by Respondent on March 2, 2015.

24 ///  
25 ///  
26 ///  
27 ///  
28 ///

1           38. On or about February 5, 2015, the IOP Interdisciplinary Treatment Plan was updated  
2 by Respondent. The update reported that Patient A was discharged as of his last date of  
3 attendance on or about February 5, 2015, due to family reunification activities out of state. The  
4 update was signed by Respondent on or about March 2, 2015. Likewise, on or about February 5,  
5 2015, Respondent issued a telephone order discharging Patient A from the IOP. The telephone  
6 order was signed by Respondent on or about March 2, 2015.

7           39. According to the discharge summary dated on or about February 5, 2015, the  
8 discharge diagnoses for Patient A were as follows: Axis I (bipolar I disorder, most recent episode  
9 depressed); Axis II (deferred); Axis III: (neurosyphilis, hyperlipidemia, GERD); Axis IV (severe,  
10 primary support and social environment); Axis V (GAF: 30). In addition, discharge psychiatric  
11 medications included Risperdal 2 mg twice daily, as well as gabapentin, paroxetine, and  
12 benztropine.

13           40. On or about February 25, 2015, Patient A was readmitted to the Alvarado Parkway  
14 Institute IOP. On or about the same day, Respondent issued a telephone order for the following  
15 psychiatric medications: Risperdal 2 mg twice daily, as well as paroxetine, benztropine, and  
16 gabapentin. The telephone order was signed by Respondent on or about March 2, 2015.

17           41. On or about March 2, 2015, Respondent made a handwritten note stating that a  
18 psychiatric evaluation was done. Respondent noted the following diagnoses: Axis I (bipolar I  
19 disorder, mixed, severe with no psychosis); Axis II (deferred); Axis III (neurosyphilis,  
20 hyperlipidemia); Axis IV (psychosocial stress secondary to mental illness); and Axis 5 (highest  
21 GAF in past year: 52, current GAF: 28). Respondent did not include any information regarding  
22 symptoms, impairments, medications, or treatment objectives for Patient A.

23           42. On or about March 4, 2015, an IOP Interdisciplinary Master Treatment Plan was  
24 prepared for Patient A. In the "Specific Causes of Functional Impairment" section, Patient A was  
25 noted to exhibit impaired cognitive functioning with memory loss, chronic cannabis abuse, and  
26 history of medication non-compliance, including present non-compliance. The treatment plan  
27 was signed by Respondent on or about May 24, 2015.

28 ///

1           43. On or about March 18, 2015, Patient A was seen by IPO physician, Dr. S.E. Changes  
2 in Patient A's mental status were noted, with intermittent episodes of confusion and poor  
3 concentration, as well as continued abuse of cannabis. Medication changes were made, including  
4 decreasing Paxil and decreasing Cogentin. Patient A was to follow up regarding the neurology  
5 consult results. On or about March 19, 2015, Patient A was also seen by IPO physician, Dr. J.C.,  
6 for a new decrease in memory.

7           44. On or about April 1, 2015, the IOP Interdisciplinary Treatment Plan was updated. The  
8 update noted that Patient A met with a psychiatrist on March 13, 2015, to discuss medications and  
9 symptoms and that four medication changes were made: "remove Paroxetine HCL for  
10 depression, Benztropine for EPS and add Paxie [sic] for depression, Cogentin for EPS." The  
11 update also noted Patient A's March 19, 2015, visit with Dr. J.C. due to his continuing struggles  
12 with memory issues, confusion, and disorganization and that he was referred to an outside  
13 medical doctor. The update was signed by Respondent on or about April 17, 2015.

14           45. On or about April 6, 2015, Respondent dictated his Psychiatric Admission Evaluation  
15 for Patient A. The note was not signed until on or about April 17, 2015. Respondent summarized  
16 Patient A's clinical history and reason for admission. The psychiatric diagnoses were noted as  
17 follows: Axis I (bipolar I disorder, mixed, severe without psychotic features; cannabis abuse);  
18 Axis II (deferred); Axis III (neurosyphilis, hyperlipidemia, gastroesophageal reflux disease); Axis  
19 IV: (psychosocial and environmental stress secondary to chronic mental illness); Axis 5 (GAF:  
20 28). The note made no mention of Patient A's reported changes in mental status and medications.

21           46. On or about April 7, 2015, Patient A presented to the nursing station stating that he  
22 did not feel well and that his primary physician recommended that he stop all of his medications,  
23 including the psychotropic medications, which Patient A agreed to do.

24           47. On or about April 17, 2015, Patient A was seen by Respondent. Respondent noted  
25 that Patient A was compliant with his medication with no side effects, was sleeping and eating  
26 better, and wished to continue with the same medications. The note indicated no medication  
27 changes. The note made no mention of Patient A's new memory problems, confusion,  
28 disorganization, medication changes, or prior reports of medication non-compliance.

1 48. On or about April 21, 2015, Patient A was seen by IPO physician, Dr. J.C. One of the  
2 reasons for the visit was Patient A's memory deficits.

3 49. On or about April 29, 2015, the IOP Interdisciplinary Treatment Plan was updated.  
4 The update reported no medication changes for the recording period. The update referenced  
5 Patient A's prior medication non-compliance as reported on or about April 7, 2015, and stated  
6 that Patient A became medication compliant a few days later and his mood improved. The update  
7 was signed by Respondent on or about May 4, 2015.

8 50. On or about May 4, 2015, Patient A was seen by Respondent. Respondent noted that  
9 Patient A was compliant with his medication with no side effects and was sleeping and eating  
10 better. The note indicated no medication changes. Respondent made no mention of Patient A's  
11 prior medication non-compliance or any discussions with Patient A regarding the adverse effects  
12 of stopping his medications.

13 51. On or about May 7, 2015, Patient A was suspended from the program for two days  
14 due to behavioral issues, including threatening behavior towards program peers.

15 52. On or about May 20, 2015, Patient A was discharged from the IOP due to his refusal  
16 to return to the program. His last date of attendance was on or about May 18, 2015. Patient A's  
17 psychiatric medications at discharge included Risperdal 2 mg twice daily, along with gabapentin,  
18 Paxil, and Cogentin. Respondent was listed as Patient A's provider on the discharge summary.  
19 The discharge summary was signed by Respondent on or about May 24, 2015.

20 53. On or about May 20, 2015, Respondent issued a telephone order discharging Patient  
21 A as of May 18, 2015. The telephone order was signed by Respondent on or about May 24, 2015.  
22 The telephone order did not include Patient A's discharge psychiatric medications.

23 54. On or about May 20, 2015, the IOP Interdisciplinary Treatment Plan was updated to  
24 reflect Patient A's discharge from the IOP. The update was signed by Respondent on or about  
25 May 24, 2015.

26 55. During Patient A's entire admission at the Alvarado Parkway Institute IOP,  
27 Respondent did not provide a plan to address Patient A's chronic cannabis use, nor did he  
28 evaluate its effects or give a rationale for not addressing it.



1           56. During the timeframe that Patient A was receiving treatment at Respondent's office  
2 and during Patient A's entire admission at the Alvarado Parkway Institute IOP, Respondent's  
3 treatment records did not contain any informed consent for psychiatric medication treatment, nor  
4 did they include any documentation of any discussion with Patient A regarding treatment  
5 objectives, potential side effects, alternatives, risks, dosage, or need for monitoring.

6           57. During the timeframe that Patient A was receiving treatment at Respondent's office  
7 and during Patient A's entire admission at the Alvarado Parkway Institute IOP, Respondent's  
8 treatment records did not contain any laboratory reports for blood levels pertaining to Depakote,  
9 orders for such testing, documentation that Patient A refused testing, or documentation that  
10 attempts were made to obtain baseline laboratory results from Patient A's prior providers or  
11 laboratory.

12           58. During the timeframe that Patient A was receiving treatment at Respondent's office  
13 and during Patient A's entire admission at the Alvarado Parkway Institute IOP, Respondent's  
14 treatment records did not reflect any discussion or decision that Respondent's treatment of Patient  
15 A had been terminated, that Respondent had notified Patient A of any such termination, whether  
16 in writing or verbally, or that Respondent provided any treatment referrals to Patient A for  
17 another provider. Respondent's treatment records also did not reflect any records of refills of  
18 Patient A's psychiatric medications following his May 20, 2015, discharge from the Alvarado  
19 Parkway Institute IOP, any treatment referrals, or any attempts to notify Patient A of the reasons  
20 for not authorizing refill requests.

21           59. Respondent committed gross negligence in his care and treatment of Patient A, which  
22 included, but was not limited to the following:

23           (a) Respondent purportedly terminated his treatment of Patient A without  
24 discussion or notification to Patient A and, following Patient A's discharge from the  
25 Alvarado Parkway Institute IOP on or about May 20, 2015, Respondent failed to refill  
26 Patient A's medications without discussion or notification to Patient A of the reasons  
27 for not authorizing refill requests and without providing Patient A with treatment  
28 referrals to another provider.

1 SECOND CAUSE FOR DISCIPLINE

2 (Repeated Negligent Acts)

3 60. Respondent has subjected his Physician's and Surgeon's Certificate No. A 67679 to  
4 disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (c), of  
5 the Code, in that he committed repeated negligent acts in his care and treatment of Patient A, as  
6 more particularly alleged in paragraphs 10 through 59, above, which are hereby incorporated by  
7 reference and re-alleged as if fully set forth herein.

8 61. Respondent committed repeated negligent acts in his care and treatment of Patient A,  
9 which included, but was not limited to the following:

10 (a) Respondent failed to obtain sufficient clinical information during Patient  
11 A's initial visit on or about June 22, 2013, to formulate an accurate psychiatric  
12 diagnosis necessary for developing an appropriate treatment plan;

13 (b) Respondent failed to obtain Patient A's informed consent for psychiatric  
14 medication treatment with Paxil, Risperdal, Depakote, Neurontin, and Cogentin  
15 during the timeframe that Patient A was receiving treatment at Respondent's office  
16 and during Patient A's entire admission at the Alvarado Parkway Institute IOP;

17 (c) Respondent failed to adequately document the rationale for changes in  
18 Patient A's treatment with psychiatric medications or that the treatment changes were  
19 discussed with Patient A during the timeframe that Patient A was receiving treatment  
20 at Respondent's office and during Patient A's entire admission at the Alvarado  
21 Parkway Institute IOP;

22 (d) Respondent failed to obtain adequate baseline laboratory studies and  
23 provide laboratory monitoring during Patient A's treatment with Depakote during the  
24 timeframe that Patient A was receiving treatment at Respondent's office and during  
25 Patient A's entire admission at the Alvarado Parkway Institute IOP;

26 (e) Respondent failed to maintain a comprehensive record of all aspects of  
27 treatment, including billing records; identifying patient information such as address,  
28 phone number, emergency contact, and power of attorney; logs or records of patient

1 phone contacts; pharmacy faxes; laboratory reports; requests for records or contact  
2 with other treating clinicians, whether attempted or made; HIPAA privacy notices;  
3 HIPAA-compliant authorizations; and informed consent for psychiatric medication  
4 treatment during the timeframe that Patient A was receiving treatment at  
5 Respondent's office;

6 (f) Respondent denied Patient A's request for refill of his Paxil on or about  
7 August 26, 2014, thereby exposing Patient A to the risk of withdrawal symptoms and  
8 decompensation in Patient A's psychiatric condition;

9 (g) Respondent failed to dictate his Psychiatric Admission Evaluation until  
10 on or about October 28, 2014, several weeks after Patient A was first admitted to the  
11 Alvarado Parkway Institute IOP;

12 (h) Respondent failed to review Patient A's treatment records, including  
13 treatment plans and updates by the treatment team, in a timely manner during Patient  
14 A's entire admission at the Alvarado Parkway Institute IOP;

15 (i) Respondent failed to dictate the Psychiatric Admission Evaluation until  
16 on or about April 6, 2015, several weeks after Patient A was readmitted to the  
17 Alvarado Parkway Institute IOP; and

18 (j) Respondent failed to recognize, acknowledge, and clinically respond to  
19 changes in Patient A's condition that were documented in the records during Patient  
20 A's readmission at the Alvarado Parkway Institute IOP.

21 **THIRD CAUSE FOR DISCIPLINE**

22 **(Failure to Maintain Adequate and Accurate Medical Records)**

23 62. Respondent has subjected his Physician's and Surgeon's Certificate No. A 67679 to  
24 disciplinary action under sections 2227 and 2234, as defined by section 2266, of the Code, in that  
25 he failed to maintain adequate and accurate records regarding his care and treatment of Patient A,  
26 as more particularly alleged in paragraphs 10 through 61, above, which are hereby incorporated  
27 by reference and re-alleged as if fully set forth herein.

28 ///

1 **FOURTH CAUSE FOR DISCIPLINE**

2 **(General Unprofessional Conduct)**

3 63. Respondent has subjected his Physician's and Surgeon's Certificate No. A 67679 to  
4 disciplinary action under sections 2227 and 2234 of the Code, in that he has engaged in conduct  
5 which breaches the rules or ethical code of the medical profession, or conduct which is  
6 unbecoming to a member in good standing of the medical profession, and which demonstrates an  
7 unfitness to practice medicine, as more particularly alleged in paragraphs 10 through 62, above,  
8 which are hereby incorporated by reference and re-alleged as if fully set forth herein.

9 **PRAYER**

10 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
11 and that following the hearing, the Medical Board of California issue a decision:


12 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 67679, issued  
13 to Respondent Yashwant S. Chaudhri, M.D.;

14 2. Revoking, suspending or denying approval of Respondent Yashwant S. Chaudhri,  
15 M.D.'s authority to supervise physician assistants, pursuant to section 3527 of the Code, and  
16 advanced practice nurses;

17 3. Ordering Respondent Yashwant S. Chaudhri, M.D., if placed on probation, to pay the  
18 Board the costs of probation monitoring; and

19 4. Taking such other and further action as deemed necessary and proper.

20  
21 DATED: February 22, 2019

  
22 KIMBERLY KIRCHMEYER  
23 Executive Director  
24 Medical Board of California  
25 Department of Consumer Affairs  
26 State of California  
27 Complainant

26 SD2019700400  
27 71753941.docx